Related Experiment Video
Updated: Jun 15, 2026
10:44
Sex Stratified Neuronal Cultures to Study Ischemic Cell Death Pathways
Published on: December 9, 2013
[Sex differences and cardiovascular drugs].
1Institutt for samfunnsmedisin, Universitetet i Tromsø, 9037 Tromsø, Norway. maja-lisa.lochen@uit.no
Summary
Cardiovascular disease (CVD) affects men and women differently. More research is needed on sex-specific drug effects, as trials often lack sufficient female participants for analysis.
Area of Science:
- Cardiovascular Science
- Pharmacology
- Sex-Based Medicine
Context:
- Cardiovascular disease (CVD) is a leading cause of mortality in Western countries.
- Significant sex-based disparities exist in CVD epidemiology, biology, and clinical presentation.
- Sex differences in pharmacological effects are gaining research attention.
Purpose:
- To highlight the importance of sex as a biological variable in cardiovascular disease research.
- To underscore the need for sex-specific analyses in pharmacological trials.
- To address the underrepresentation of women in clinical trials.
Summary:
- CVD exhibits notable sex-based differences in its occurrence, biological underpinnings, and clinical manifestations.
- While clinical trials include both sexes, women are often underrepresented, hindering sex-specific pharmacological analyses.
- Understanding these sex-based variations is crucial for effective CVD treatment and drug development.
Impact:
- Informing the development of sex-specific therapeutic strategies for cardiovascular disease.
- Improving the efficacy and safety of pharmacological interventions by considering sex differences.
- Advancing personalized medicine approaches in cardiovascular health through sex-based research.
More Related Videos
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:19Factors Affecting Drug Biotransformation: Biological
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...